Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 5/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | NOS3 | P29474 | 2/20 | 0.33 |
| ▸ | NOS2 | P35228 | 2/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30358244 | 0.72 | TRPA1 (0.38) | TRPA1BRD4CREBBPCYP2D6MEN1 | |
| SCHEMBL7422184 | 0.72 | BRD4 (0.38) | BRD4CREBBPCYP2D6MEN1RECQL | |
| SCHEMBL13620740 | 0.72 | TRPA1 (0.38) | TRPA1BRD4CREBBPCYP2D6MEN1 | |
| SCHEMBL20404734 | 0.72 | TRPA1 (0.38) | TRPA1BRD4CREBBPCYP2D6MEN1 | |
| SCHEMBL7422185 | 0.72 | BRD4 (0.38) | BRD4CREBBPCYP2D6MEN1RECQL | |
| SCHEMBL13604087 | 0.69 | NOS1 (0.48) | NOS3NOS2NOS1SMN1; SMN2ALDH1A1 | |
| SCHEMBL315647 | 0.69 | BRD4 (0.54) | BRD4CREBBPNOS3NOS2ACHE | |
| SCHEMBL840754 | 0.69 | NOS3 (0.47) | TRPA1BRD4CREBBPCYP2D6MEN1 | |
| SCHEMBL8946067 | 0.68 | TSHR (0.40) | TRPA1BRD4CREBBPCYP2D6MEN1 | |
| SCHEMBL60763 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200031798-A1 | BENZAZEPINE COMPOUNDS, CONJUGATES, AND USES THEREOF | ARS Pharmaceuticals, Inc. | 2020-01-30 | — | — | US | disclosed |
| US-10428045-B2 | Benzazepine compounds, conjugates, and uses thereof | SILVERBACK THERAPEUTICS, INC. (US) | 2019-10-01 | — | — | US | disclosed |
| US-20190169165-A1 | BENZAZEPINE COMPOUNDS, CONJUGATES, AND USES THEREOF | SILVERBACK THERAPEUTICS, INC. | 2019-06-06 | — | — | US | disclosed |
| US-20190169164-A1 | BENZAZEPINE COMPOUNDS, CONJUGATES, AND USES THEREOF | SILVERBACK THERAPEUTICS, INC. | 2019-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190169164-A1 | BENZAZEPINE COMPOUNDS, CONJUGATES, AND USES THEREOF | TLR8, TLR3, TLR5 | TRPA1 182/4885BRD4 34/4885CREBBP 319/4885 |
| US-10428045-B2 | Benzazepine compounds, conjugates, and uses thereof | TLR8, TLR3, TLR5 | TRPA1 182/4885BRD4 34/4885CREBBP 319/4885 |
| US-20200031798-A1 | BENZAZEPINE COMPOUNDS, CONJUGATES, AND USES THEREOF | TLR8, TLR3, TLR5 | TRPA1 182/4885BRD4 34/4885CREBBP 319/4885 |
| US-20190169165-A1 | BENZAZEPINE COMPOUNDS, CONJUGATES, AND USES THEREOF | TLR8, TLR3, TLR5 | TRPA1 182/4885BRD4 34/4885CREBBP 319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.